Detail akcie Pharming Group online

Business Summary: Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Pharming Group NV revenues increased 32% to $269.6M. Net loss applicable to common stockholders decreased 83% to $2.5M. Revenues reflect RUCONEST segment increase of 34% to $231.2M, Joenja segment increase of 20% to $38.4M, US segment increase of 33% to $262M, Europe & ROW segment increase of 2% to $7.6M. Lower net loss reflects Equity Earnings -Before Taxes decrease of 78% to $279K (expense).